The Effects of Pharmacologic Agents for Type 2 Diabetes Mellitus on Body Weight
- 1 January 2008
- journal article
- review article
- Published by Taylor & Francis Ltd in Postgraduate Medicine
- Vol. 120 (2), 5-17
- https://doi.org/10.3810/pgm.2008.07.1785
Abstract
Type 2 diabetes mellitus and obesity share a pathogenic relationship, and both have rapidly increased in prevalence over the past decade. This review evaluates the effects of antidiabetes therapies on weight and glycemic control in the type 2 diabetes mellitus population. A PubMed search was conducted to identify randomized controlled trials that reported the weight effects of antidiabetes treatments. The search focused on the newer incretin-based therapies, including dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) agonists. Antiobesity drugs and treatment options potentially available to patients with type 2 diabetes mellitus, including bariatric surgery, were also examined. Most of the established antidiabetes therapies (eg, sulfonylureas, thiazolidinediones) promote weight gain, thereby exacerbating insulin resistance and glucose intolerance. Dipeptidyl peptidase-4 inhibitors exhibit a weight-neutral profile, however, and GLP-1 receptor agonists (eg, exenatide, liraglutide) have achieved significant body weight reductions in spite of improved glycemic control, which is often accompanied by weight gain. Antiobesity drugs, such as orlistat and sibutramine, are effective weight-lowering agents in patients with type 2 diabetes mellitus, but safety and tolerability concerns may limit their use. Bariatric surgery in obese patients is associated with improved glycemic values and decreased mortality. Clinical evidence substantiating the weight-neutral effects of DPP-4 inhibitors and the weight-loss effects of GLP-1 agonists is promising, offering an expansion of therapeutic options for overweight and obese patients with type 2 diabetes mellitus. Evidence on the clinical utility of antiobesity drugs is more equivocal, and more data are needed to evaluate the safety and tolerability of these agents.Keywords
This publication has 99 references indexed in Scilit:
- A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetesDiabetologia, 2008
- Long term pharmacotherapy for obesity and overweight: updated meta-analysisBMJ, 2007
- Long-Term Mortality after Gastric Bypass SurgeryThe New England Journal of Medicine, 2007
- Effects of Bariatric Surgery on Mortality in Swedish Obese SubjectsThe New England Journal of Medicine, 2007
- Efficacy and Safety of Incretin Therapy in Type 2 DiabetesJAMA, 2007
- Obesity and Diabetes in the Developing World — A Growing ChallengeThe New England Journal of Medicine, 2007
- Does insulin detemir have a role in reducing risk of insulin‐associated weight gain?Diabetes, Obesity and Metabolism, 2006
- Prevalence of Overweight and Obesity in the United States, 1999-2004JAMA, 2006
- SibutramineDrugs, 1998
- A Prospective Study of Obesity and Risk of Coronary Heart Disease in WomenThe New England Journal of Medicine, 1990